MARÍA LUZ LÓPEZ RODRÍGUEZ-rekin lankidetzan egindako argitalpenak (24)

2021

  1. Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson-Gilford Progeria Syndrome

    ACS Central Science, Vol. 7, Núm. 8, pp. 1300-1310

2020

  1. Glucose metabolism links astroglial mitochondria to cannabinoid effects

    Nature, Vol. 583, Núm. 7817, pp. 603-608

2019

  1. A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia

    Journal of Medicinal Chemistry, Vol. 62, Núm. 13, pp. 6035-6046

2018

  1. Development of a Fluorescent Bodipy Probe for Visualization of the Serotonin 5-HT 1A Receptor in Native Cells of the Immune System

    Bioconjugate Chemistry, Vol. 29, Núm. 6, pp. 2021-2027

  2. A Fluorescent Probe to Unravel Functional Features of Cannabinoid Receptor CB1 in Human Blood and Tonsil Immune System Cells

    Bioconjugate Chemistry, Vol. 29, Núm. 2, pp. 382-389

2015

  1. New inhibitors of angiogenesis with antitumor activity in vivo

    Journal of Medicinal Chemistry, Vol. 58, Núm. 9, pp. 3757-3766

2014

  1. The expression of cannabinoid receptor 1 is significantly increased in atopic patients

    Journal of Allergy and Clinical Immunology, Vol. 133, Núm. 3

2013

  1. New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo

    Journal of Medicinal Chemistry, Vol. 56, Núm. 20, pp. 7851-7861

2011

  1. New serotonin 5-HT 1A receptor agonists with neuroprotective effect against ischemic cell damage

    Journal of Medicinal Chemistry, Vol. 54, Núm. 23, pp. 7986-7999

2007

  1. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions

    Life Sciences, Vol. 80, Núm. 10, pp. 979-988

2006

  1. Chronic Δ9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex

    Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 372, Núm. 4, pp. 313-317

  2. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders

    European Neuropsychopharmacology, Vol. 16, Núm. 1, pp. 7-18

2004

  1. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: Synthesis of new transporter inhibitors as tools for this study

    British Journal of Pharmacology, Vol. 141, Núm. 3, pp. 457-467

  2. Synthesis and structure-activity relationships of a new model of arylpiperazines. Part 7: Study of the influence of lipophilic factors at the terminal amide fragment on 5-HT1A affinity/selectivity

    Bioorganic and Medicinal Chemistry, Vol. 12, Núm. 6, pp. 1551-1557

2003

  1. Optimization of the Pharmacophore Model for 5-HT 7 R Antagonism. Design and Synthesis of New Naphtholactam and Naphthosultam Derivatives

    Journal of Medicinal Chemistry, Vol. 46, Núm. 26, pp. 5638-5650

  2. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors

    European Journal of Medicinal Chemistry

  3. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase

    Journal of Medicinal Chemistry, Vol. 46, Núm. 8, pp. 1512-1522

  4. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 18, Núm. 3, pp. 225-231

2002

  1. Endocannabinoid transporter inhibitors

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 2, Núm. 2, pp. 129-141

  2. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide

    European Journal of Pharmacology, Vol. 449, Núm. 1-2, pp. 99-103